Triple Agonist Peptide (GLP-1 / GIP / Glucagon) | Powerful Fat Loss, Metabolic Optimization & Glycaemic Support | For Research Use Only

Retatrutide is a novel triple receptor agonist that activates GLP-1, GIP, and Glucagon receptors, offering unmatched synergy in metabolic peptide research. This multifaceted action leads to accelerated fat loss, significant appetite suppression, and enhanced energy expenditure, making it a highly valuable compound for studies in obesity, insulin resistance, and type 2 diabetes.

The 30mg format offers a balanced option for weekly dosing in long-term weight management and metabolic function studies.

🔍 Key Features

• Triple Action: GLP-1 + GIP + Glucagon Receptor Agonist

• Reduces Appetite & Enhances Satiety Signals

• Promotes Fat Oxidation & Lean Mass Preservation

• Improves Insulin Sensitivity & Glycaemic Control

• Outperforms GLP-1 Monotherapies in Early Research Models

• Supports Long-Term Obesity & Metabolic Disease Research

⚙️ Compound Details

• Compound Name: Retatrutide

• CAS Number: 2381089-83-2

• Molecular Formula: C₂₀₉H₃₂₉N₅₅O₆₆

• Molecular Weight: ~4717.35 g/mol

• Purity: ≥ 98% (HPLC Verified)

• Form: Lyophilised powder

• Unit Size: 30mg per vial

🧊 Storage & Handling

• Storage (lyophilised): Store at –20°C in a cool, dry, and dark environment

• Reconstitution: Reconstitute with 1–2ml sterile bacteriostatic water

• Post-Reconstitution: Store at 2–8°C and use within 10–14 days

• Avoid: Heat, light, and repeated freeze-thaw cycles

⚠️ For Research Use Only

Retatrutide – 30mg is intended strictly for scientific research and investigational use. It is not for human use, therapeutic treatment, or diagnostic purposes.